Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
96 hedge funds and large institutions have $49.4M invested in Endocyte, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 10 closing their positions.
491% more call options, than puts
Call options by funds: $260K | Put options by funds: $44K
1% less capital invested
Capital invested by funds: $49.7M → $49.4M (-$260K)
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
1% less funds holding
Funds holding: 97 → 96 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.86M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$247K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$192K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$145K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$76.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$2.07M |
| 2 |
Millennium Management
New York
|
-$1.09M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$558K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$412K |
| 5 |
Morgan Stanley
New York
|
-$355K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
LPL Financial
San Diego,
California
| – | -$42K | -13,060 | Closed |
|
102
Group One Trading
Chicago,
Illinois
| – | -$5.85K | -1,597 | Closed |
|
103
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$4K | -1,352 | Closed |
|
|
PRS
104
Pinkerton Retirement Specialists
Coeur D Alene,
Idaho
| – | +$103 | +28 | New |
|
|
CG
105
Cutler Group
San Francisco,
California
| – | +$733 | +200 | New |
|
ECYT Hedge Fund Activity: Q2 2016 in Review
96 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2016, worth a combined $49.4M — down 0.52% from $49.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ECYT and 9 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 28 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.86M. The largest seller was Baker Bros. Advisors, cutting an estimated $2.07M.
- 96 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2016, down from 97 in Q1 2016.
- Funds reported $49.4M of Endocyte, Inc. Common Stock stock for Q2 2016, down 0.52% quarter-over-quarter.
- 9 funds opened new Endocyte, Inc. Common Stock positions in Q2 2016 and 10 closed out, a net change of -1 holder.
- The largest Endocyte, Inc. Common Stock buyer in Q2 2016 was JP Morgan Chase, an estimated $2.86M added.
- The largest Endocyte, Inc. Common Stock seller in Q2 2016 was Baker Bros. Advisors, an estimated $2.07M sold.
Based on aggregated 13F filings for Q2 2016.